CMMB - Chemomab Therapeutics - ADR GAAP EPS of -$0.027 August, 12 2022 06:14 AM Chemomab Therapeutics Ltd. Chemomab Therapeutics - ADR press release ( NASDAQ: CMMB ): Q2 GAAP EPS of -$0.027. Cash, cash equivalents and bank deposits were $51.8 million as of June 30, 2022, compared to $57.5 million at March 31, 2022. For further details see: Chemomab Therapeutics - ADR GAAP EPS of -$0.027